- Home
- SKT vs ELVN Comparison
SKT vs ELVN Comparison
Compare SKT & ELVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SKT | ELVN |
|---|---|---|
| Founded | 1981 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.7B | 4.2B |
| IPO Year | 1994 | 2020 |
Fundamental Metrics
Financial Performance| Metric | SKT | ELVN |
|---|---|---|
| Price | $38.57 | $60.88 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 6 | 5 |
| Target Price | $37.17 | ★ $43.40 |
| AVG Volume (30 Days) | 789.5K | ★ 1.0M |
| Earning Date | 04-30-2026 | 05-11-2026 |
| Dividend Yield | ★ 3.18% | N/A |
| EPS Growth | N/A | ★ 3.17 |
| EPS | ★ 0.53 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $0.37 | N/A |
| Revenue Next Year | $3.90 | N/A |
| P/E Ratio | $73.47 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $31.13 | $14.79 |
| 52 Week High | $42.53 | $62.32 |
Technical Indicators
Market Signals| Indicator | SKT | ELVN |
|---|---|---|
| Relative Strength Index (RSI) | 45.23 | 68.47 |
| Support Level | $38.43 | $56.69 |
| Resistance Level | $41.27 | $62.32 |
| Average True Range (ATR) | 0.61 | 1.98 |
| MACD | -0.04 | -0.11 |
| Stochastic Oscillator | 40.00 | 96.33 |
Price Performance
Historical ComparisonAbout SKT Tanger Inc.
Tanger Inc is an owner and operator of outlet and open-air centers in the United States and Canada. It is a fully-integrated, self-administered and self-managed REIT, which focuses on developing, acquiring, owning, operating and managing outlet and open-air shopping centers. Its consolidated portfolio consisted of 31 outlet centers and 2 open-air lifestyle centers.
About ELVN Enliven Therapeutics Inc.
Enliven Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics. The product candidates of the company include ELVN-001 is designed to specifically target the BCR-ABL fusion gene product, the oncogenic driver for patients with chronic myeloid leukemia (CML), ELVN-002 is designed to inhibit wild-type HER2 and key mutations of HER2.